Skip to Main Content

Paper Details

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Mol Cancer
14
2022
ALK, ALK-mutated neuroblastomas, ALKi, Cas9, MAPK, MEK, NF1, NRAS, RAS, RAS mutations, anaplastic, anaplastic lymphoma kinase, cancer, cell line models, childhood cancer, human, human neuroblastomas, neuroblastoma, neuroblastoma cell line NBLW-R, neuroblastoma cell lines, neuroblastoma cells, neuroblastomas, patients, resistance, resistant cells, tumor
Author NameAffiliation
Elias Rodriguez-FosCharite - Universitatsmedizin Berlin
Elias Rodriguez-FosExperimental and Clinical Research Center (ECRC) of the Charite and Max-Delbruck-Center for Molecular Medicine (MDC) in the Helmholtz Association
Jan J MolenaarPrincess Maxima Center for Pediatric Oncology
Jan J MolenaarDepartment of pharmaceutical sciences, Utrecht University
Matthias FischerCenter for Molecular Medicine Cologne
Matthias FischerCenter for Molecular Medicine Cologne
Angelika EggertCharite - Universitatsmedizin Berlin
Angelika Eggert
Angelika EggertGerman Cancer Research Center (DKFZ)
Angelika EggertBerlin Institute of Health (BIH) at Charite-Universitatsmedizin Berlin
Anton G HenssenCharite - Universitatsmedizin Berlin
Anton G HenssenExperimental and Clinical Research Center (ECRC) of the Charite and Max-Delbruck-Center for Molecular Medicine (MDC) in the Helmholtz Association
Anton G Henssen
Anton G HenssenGerman Cancer Research Center (DKFZ)
Anton G HenssenBerlin Institute of Health (BIH) at Charite-Universitatsmedizin Berlin
Johannes H SchulteCharite - Universitatsmedizin Berlin
Johannes H Schulte
Johannes H SchulteGerman Cancer Research Center (DKFZ)
  • 1 - 18

Datasets

Release 1.2